左心室辅助装置植入时对重度二尖瓣反流行二尖瓣修复的结局
本研究比较了78例在LVAD植入时系统行二尖瓣修复的重度MR患者与28例历史对照(未处理MR),发现MVr不增加围术期不良事件,且3个月时无患者MR超过轻度,2年心衰再入院累积发生率更低(7.1% vs 19.7%)。
要点
- LVAD植入时同期行MVr安全,不增加30天死亡及早期主要不良事件。
- MVr组3个月时无患者MR超过轻度,非MVr组有7例(29%)。
- MVr组2年心衰再入院累积发生率更低(7.1% vs 19.7%)。
核心结论
- LVAD植入时同期行MVr可安全实施,不增加围术期不良事件。
- MVr可能更好地减轻MR严重程度,并可能降低心衰再入院。
研究设计与样本
- 单中心回顾性研究,78例2013-2017年LVAD植入时行MVr的重度MR患者。
- 对照为2011-2013年28例未处理MR的重度MR患者,采用Cox模型和倾向评分方法。
- 中位随访时间17.7个月。
主要发现
- MVr组患者较非MVr组年轻(55 vs 63岁;P = .006),其余术前特征相似。
- 30天死亡率(2.6% vs 3.6%;P = .78)及其他早期主要不良事件两组相似。
- 3个月时MVr组无患者MR超过轻度,非MVr组有7例(29%)(P < .001)。
- 术后3-6个月心导管显示MVr组肺动脉收缩压较术前下降更多(-20 vs -13 mm Hg;P = .10)。
- 2年心衰再入院累积发生率MVr组低于非MVr组(7.1% vs 19.7%;调整后风险比0.18;95%CI 0.04-0.76;P = .02)。
临床怎么用
- 对于LVAD植入合并重度MR的患者,可考虑同期行二尖瓣修复。
- 同期MVr不增加围术期风险,可能减少心衰再入院。
局限性
- 非随机对照,使用历史对照,可能存在选择偏倚。
- 样本量较小,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of severe mitral regurgitation (MR) at the time of left ventricular assist device (LVAD) implantation is controversial. We adopted an approach of systematic repair of severe MR at the time of LVAD implantation and report our experience. METHODS: We performed mitral valve repair (MVr) on 78 consecutive patients with severe MR undergoing LVAD implantation at our institution between 2013 and 2017. We compared data on these patients to 28 historical controls with severe MR from the immediate preceding period between 2011 and 2013 where the MR was not treated, using Cox modeling and propensity score methods. Median follow-up time was 17.7 months. RESULTS: Patients who underwent MVr were younger than those who did not (non-MVr group) (55 vs 63 years; P = .006), but otherwise had similar preoperative characteristics. The incidence of 30-day mortality (2.6% vs 3.6%; P = .78) and other early major adverse events was similar in both groups. At 3 months, no patient in the MVr group had more than mild MR compared with 7 patients (29%) in the non-MVr group (P < .001). Cardiac catheterization done 3 to 6 months after surgery showed tendency toward greater reduction from preoperative pulmonary artery systolic pressure in the MVr group compared with the non-MVr group (-20 vs -13 mm Hg; P = .10). The cumulative incidence of readmission due to congestive heart failure at 2 years was lower in the MVr group than in non-MVr group (7.1% vs 19.7%; adjusted hazard ratio, 0.18; 95% confidence interval, 0.04-0.76; P = .02). CONCLUSIONS: Concurrent MVr at the time of LVAD implantation can be done safely without increase in perioperative adverse events. MVr may be associated with better reduction in severity of MR and may have potential benefit in terms of reduction in readmissions for heart failure.
引用
- Pawale A, Itagaki S, Parikh A, et al. Mitral valve repair for severe mitral valve regurgitation during left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2018. PMID: 31288361. doi:10.1016/j.jtcvs.2018.12.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。